Novartis Tightens Stance Over Gleevec In India

By Erin Marie Daly (February 15, 2007, 12:00 AM EST) -- Novartis AG on Thursday strengthened its stance on patenting its cancer treatment Gleevec in India, arguing that a modification to a key section of the country's patent laws governing whether companies can protect new versions of drugs whose patents have expired would not hinder the supply of essential medicines to poor countries....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!